Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.

Yoshiya TanakaSatoshi SoenNaoki IshiguroHisashi YamanakaToshiyuki YonedaSakae TanakaTakeshi OhiraTakaya NittaNaoki OkuboHarry GenantDésirée Mfm van der HeijdeTsutomu Takeuchi

Published in: RMD open (2021)

Denosumab broadly reduced the progression of joint destruction in RA patients with risk factors for radiographic damage such as especially anti-CCP antibody positivity.

Keyphrases

rheumatoid arthritis
bone mineral density
disease activity
giant cell
randomized controlled trial
interstitial lung disease
postmenopausal women
immune response
inflammatory response
bone loss